US Patent

US10967077 — Imaging of metastatic or recurrent cancer

Method of Use · Assigned to Blue Earth Diagnostics Ltd · Expires 2035-12-30 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using the drug [18F]-FACBC for imaging, diagnosing, and monitoring metastatic or recurrent cancer.

USPTO Abstract

The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2450`	—

Patent Metadata

Patent number: US10967077
Jurisdiction: US
Classification: Method of Use
Expires: 2035-12-30
Drug substance claim: No
Drug product claim: No
Assignee: Blue Earth Diagnostics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.